Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments.

Another objective of the trial is to assess and compare the safety of each treatment.
Colorectal Cancer
DRUG: XELODA|DRUG: TEGAFUR URACIL - FOLINIC ACID
patients preference after randomization and cross-over, after 2 cycles of treatment
safety of each treatment, at day 56 (after two cycles of treatment)
Further study details as provided by Centre Oscar Lambret.